Each Tablet contains: Betahistine Hydrochloride 16 mg.
Pharmacology: Betahistine is an analogue of histamine and is claimed to improve the microcirculation of the labyrinth resulting in reduced endolymphatic pressure.
Pharmacokinetics: Betahistine Hydrochloride is completely absorbed after oral administration. It only has one metabolite, 2 pyridylacetic acid which is excreted in the urine.
It is used for the treatment of vertigo, tinnitus, and hearing loss associated with Meniere's disease.
Initial dose: 16 mg three times daily taken preferably with meals.
Maintenance dose: 24 mg to 48 mg daily.
Or as prescribed by physician.
Patients with phaeochromocytoma should not be given betahistine. It should also be given with care to patients with asthma, peptic ulcer disease, or a history of peptic ulcer disease.
Gastrointestinal disturbances, headaches, skin rashes and pruritus have been reported.
Store at temperatures not exceeding 30°C.
N07CA01 - betahistine ; Belongs to the class of antivertigo preparations.